Pharmaceutical ERA•Regulatory Toxicology•PDE / OEL
[email protected]
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Abacavir→

Abacavir Environmental Risk Assessment (ERA)

General class/use (background only): Nucleoside analogue reverse transcriptase inhibitor used with other antiretroviral medicines in HIV treatment. The applicable product label defines the authorised use. Specific authorised uses depend on the applicable product label and jurisdiction. PubChem source.

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
136470-78-5
Molecular formula
C14H18N6O
Molecular weight
286.33 g/mol

Related pharmaceutical form(s) (name only): Abacavir sulfate. Its identifiers are not merged into the main identity; confirm exact substance form before assessment use.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other markets
About this profile

Scope of the Abacavir ERA assessment

This ToxWriter profile covers the scope for a project-specific Environmental Risk Assessment (ERA) report for Abacavir. The relevant assessment pathway depends on product context, maximum daily dose, regulatory jurisdiction and available environmental fate and ecotoxicity evidence.

Typical scientific scope

  • Phase I environmental exposure assessment and trigger evaluation.
  • Phase II environmental fate, effects and risk characterisation where further assessment is required.
  • Predicted environmental concentration (PEC) and predicted no-effect concentration (PNEC) considerations, as applicable.
  • PBT/vPvB considerations and tailored environmental assessment strategies where relevant.
Scope noteThis page outlines ToxWriter’s environmental risk assessment support for Abacavir. The product, intended market and available environmental evidence determine the scope of any project-specific assessment.
Project adaptation

Scope the profile to your submission.

Existing assessment material may be reviewed and, where appropriate, adapted to the intended product and regulatory context. Public summaries are not automatically a substitute for underlying study data or access rights.

  • Product and intended-market review.
  • Assessment pathway and data-gap review.
  • Market-specific calculation and documentation considerations.
  • Structured final report within the agreed scope.
ERA regulatory framework
ERA background →EMA environmental risk assessment guideline · EU human medicinesMHRA environmental risk assessments in medicines · UK

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.

ERAPDE / ADEOEL / OEB